Treating Alzheimer'S disease: Pharmacologic options now and in the near future

Postgraduate Medicine

Volumn 101, Issue 6, 1997, Pages 73-90

  Tariot, Pierre N ^a   Schneider, Lon ^b   Porsteinsson, Anton P ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUSPIRONE; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; DONEPEZIL; HALOPERIDOL; NEUROLEPTIC AGENT; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; SYNAPTON; TACRINE; THIORIDAZINE; TRAZODONE; UNCLASSIFIED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID;

ALZHEIMER DISEASE; BRAIN METABOLISM; CONFERENCE PAPER; CONVULSION; DEPRESSION; HUMAN; NEUROTRANSMISSION; PSYCHOSIS; TREATMENT PLANNING;

AGED; ALZHEIMER DISEASE; DRUG THERAPY, COMBINATION; HUMANS; MIDDLE AGED; NEUROTRANSMITTER AGENTS;

EID: 1842375076     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.1997.06.224     Document Type: Article

References (22)

1. Tariot PN. Neurobiology and treatment of dementia. In: Salzman C, ed. Clinical geriatric psychopharmacology. 2d ed. Baltimore: Williams & Wilkins, 1992: 277 – 99
2. Tariot PN, Schneider LS, Coleman PD. Treatment of Alzheimer's disease: glimmers of hope? Chem Indus 1993; 20: 801 – 7
3. Schneider LS, Tariot PN. Emerging drugs for Alzheimer's disease: mechanisms of action and prospects for cognitive enhancing medications. Med Clin North Am 1994; 78 (4): 911 – 34
4. Schneider LS, Tariot PN. Cognitive enhancers for Alzheimer's disease. In: Tasman A, Kay J, Lieberman J, eds. Psychiatry. Philadelphia: Saunders, 1997: 1685 – 1702
5. Tariot PN, Schneider LS. Contemporary treatment approaches to Alzheimer's disease. Consult Pharm 1996; 11 (Suppl E): 16 – 24
6. Schneider LS, Tariot PN, Small GW. Update on treatment for Alzheimer's disease and other dementias. In: Rosenbaum J, Dunner D, eds. Psychiatr Clin North Am: Annual of Drug Therapy. Philadelphia: Saunders, 1997: 135 – 66
7. Tariot PN, Schneider LS, Katz IR. Anticonvulsant and other non-neuroleptic treatment of agitation in dementia. J Geriatr Psychiatry Neurol 1995; 8 (Suppl 1): S28 – 39
8. Tariot PN. Treatment strategies for agitation and psychosis in dementia. J Clin Psychiatry 1996; 57 (Suppl 14): 21 – 9
9. Harrell LE, Callaway R, Morere D, et al. The effect of long-term physostigmine administration in Alzheimer's disease. Neurology 1990; 40 (9): 1350 – 4
10. Summers WK, Majovski LV, Marsh GM, et al. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med 1986; 315 (20): 1241 – 5
11. Tacrine Study Group. A controlled trial of tacrine in Alzheimer's disease. JAMA 1992; 268 (18): 2523 – 9
12. Tacrine Study Group. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994; 271 (13): 985 – 91
13. Tacrine Study Group. Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality. Neurology 1996; 47 (1): 166 – 77
14. Kaufer DI, Cummings JL, Christine D. Effect of tacrine on behavioral symptoms in Alzheimer's disease: an open-label study. J Geriatr Psychiatry Neurol 1996; 9 (1): 1 – 6
15. Rogers SL, Friedhoff LT. E2020 improves cognition and quality of life in patients with mild-to-moderate Alzheimer's disease: results of a phase-II trial. Neurology 1994; 44 (Suppl 2): A165
16. Rogers SL, Doody R, Mohs R, et al. E2020 produces both clinical global and cognitive test improvement in patients with mild to moderately severe Alzheimer's disease: results of a 30-week phase III trial. Neurology 1996; 46: A217
17. Rogers SL, Friedhoff LT. Donepezil (E2020) produces long-term clinical improvement in Alzheimer's disease. Presented at the 4th International Nice/Springfield Symposium on Advances in Alzheimer Therapy. Nice, France: 1996 Apr
18. Anand R, Gharabawi G. Efficacy and safety results of the early phase studies with Exelon (ENA 713) in Alzheimer's disease: an overview. J Drug Dev Clin Practice 1996; 8: 1 – 14
19. Tariot PN, Schneider LS, Patel SV, et al. Alzheimer's disease and (-)deprenyl: rationales and findings. In: Szelenyi I, ed. Inhibitors of monoamine oxidase B: pharmacology and clinical use in neurodegenerative disorders. Basel, Switzerland: Birkhauser 1993: 301 – 17
20. Olsson L, Nordberg A, Von Holst H, et al. Nerve growth factor affects “C-nicotine binding, blood flow, EEG, and verbal episodic memory in an Alzheimer patient (case report). Neurobiol Aging 1989; 10: 205 – 7
21. Ohkura T, Isse K, Akazawa K, et al. Evaluation of estrogen treatment in female patients with dementia of the Alzheimer type. Endocr J 1994; 41 (4): 361 – 71
22. Aisen PS, Davis KL. Inflammatory mechanisms in Alzheimer's disease: implications for therapy. Am J Psychiatry 1994; 151 (8): 1105 – 13